Cahaba Wealth Management Inc. Has $203,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Cahaba Wealth Management Inc. trimmed its holdings in Bristol-Myers Squibb (NYSE:BMYFree Report) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,963 shares of the biopharmaceutical company’s stock after selling 540 shares during the quarter. Cahaba Wealth Management Inc.’s holdings in Bristol-Myers Squibb were worth $203,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of BMY. Herold Advisors Inc. increased its position in shares of Bristol-Myers Squibb by 3.2% during the third quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company’s stock valued at $1,954,000 after purchasing an additional 1,051 shares during the period. Osterweis Capital Management Inc. boosted its position in shares of Bristol-Myers Squibb by 69.6% during the 2nd quarter. Osterweis Capital Management Inc. now owns 5,049 shares of the biopharmaceutical company’s stock valued at $323,000 after acquiring an additional 2,072 shares in the last quarter. Kestra Private Wealth Services LLC increased its stake in Bristol-Myers Squibb by 9.5% in the third quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company’s stock valued at $8,115,000 after acquiring an additional 12,121 shares during the period. Metis Global Partners LLC raised its position in Bristol-Myers Squibb by 14.8% in the third quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company’s stock worth $5,907,000 after purchasing an additional 13,122 shares in the last quarter. Finally, Jmac Enterprises LLC lifted its stake in Bristol-Myers Squibb by 11.4% during the third quarter. Jmac Enterprises LLC now owns 12,171 shares of the biopharmaceutical company’s stock worth $706,000 after purchasing an additional 1,245 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Down 0.5 %

Shares of NYSE:BMY traded down $0.24 during trading on Tuesday, hitting $52.75. 10,233,247 shares of the company’s stock traded hands, compared to its average volume of 16,652,035. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The company has a 50-day moving average price of $51.03 and a 200-day moving average price of $52.25. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $71.07. The company has a market cap of $106.91 billion, a price-to-earnings ratio of 13.72, a price-to-earnings-growth ratio of 1.64 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. During the same quarter in the previous year, the firm posted $1.82 earnings per share. The business’s revenue was up .6% on a year-over-year basis. As a group, research analysts forecast that Bristol-Myers Squibb will post 6.61 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.55%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 62.18%.

Bristol-Myers Squibb declared that its board has authorized a stock repurchase program on Thursday, December 7th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BMY shares. Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the stock from $68.00 to $60.00 in a research report on Wednesday, January 3rd. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $61.12.

View Our Latest Stock Analysis on BMY

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read More

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.